At Verthermia®, our mission is to extend and enhance life for people with advanced unresponsive cancer. We also pledge to continue investigating how our natural process can fight deadly diseases and viruses, in addition to cancer treatment. Through our perseverance and motivation, we vow to always provide safe, effective treatment and minimize side effects.
Verthermia's management team is responsible for overseeing all medical operations and ensuring that our treatment protocols are in line with the latest advancements in the field. Our team is composed of professionals from the medical and business worlds. Working in tandem with our staff of highly trained professionals, our management team provides the foundation for Verthermia's operational and medical efficiency.
Our board of directors consists of passionate, dedicated individuals with a wealth of experience in the areas of cancer and hyperthermia treatments. We are proud to have a diverse board that provides insight into various aspects of cancer care. They are integral to our mission of providing patients with exceptional treatment.
Combining cutting-edge technology with evidence-based treatment, the medical advisory board at Verthermia includes top minds of cancer treatment. Our team is composed of experienced specialists and scientists who are committed to helping our patients achieve positive outcomes. Collectively, they bring a wealth of knowledge and experience to the table, allowing us to stay ahead of emerging trends in hyperthermia cancer treatment.
HEATT® has been evaluated in two Phase one FDA clinical trials. On the most recent ovarian cancer trial, the FDA expressed “no comments or concerns”. Verthermia® recognizes the importance of conducting clinical trials to evaluate the effectiveness of our hyperthermia cancer treatments. We are committed to continuously improving our therapies and exploring innovative approaches for treating various forms of cancer. Our team of dedicated researchers evaluates our data-driven solutions that will not only benefit current patients but also pave the way for better treatments for future generations.
Our ovarian cancer trial resulted in significant findings on the positive impacts of HEATT®. Patients overall experienced improved survival rates and daily living satisfaction.
Verthermia® trial patients with unresponsive lung cancer exceeded average life expectancy after receiving HEATT®.
The system and methods of Verthermia® are protected by four issued US patents (11,065,379; 11,185,622; 11,191,883, and 11,239,551). Two other US patent applications are in process, and one international or PCT (Patent Cooperation Treaty) application is in process. Verthermia® has two registered US trademarks, and two other US trademark applications are in process. Verthermia has also filed an application for an international trademark. We have a robust intellectual property policy, and Verthermia® protects some of its proprietary methods as trade secrets. All documents, procedures, websites, and presentations are copyrighted by Verthermia®. Roger and Jan are co-inventors of the CORE-HFC® device which delivers HEATT®.